doi:10.3969/j.issn.1673-8640.2019.08.019

Abstract

CLC Number:

R446.1

. [J]. Laboratory Medicine, 2019, 34(8): 763-764.

Figures/Tables 2

References 10

[1]	邢燕,宋红梅,吴晓燕,等. 慢性活动性EB病毒感染患儿外周血单个核细胞EB病毒DNA及感染细胞类型检测的临床意义[J]. 中华儿科杂志,2011,49(7):495-500.
[2]	谢正德,申昆玲. 重视儿童非肿瘤性EB病毒感染疾病的研究[J]. 首都医科大学学报,2010,31(2):213-216.
[3]	郭霞,李强,周晨燕,等. 儿童EB病毒感染相关性噬血细胞综合征临床特点分析[J]. 中国实验血液学杂志,2013,21(2):460-464.
[4]	肖静宇,姚基伟,程力平. EB病毒感染相关疾病的临床检验方法[J]. 现代中西医结合杂志,2011,20(28):3634-3636.
[5]	高立伟,谢正德,幺远,等. 儿童EB病毒感染传染性单核细胞增多症的临床特征[J]. 实用儿科临床杂志,2010,25(10):725-727.
[6]	林英辉. 传染性单核细胞增多症患儿EBV-DNA检测及其意义[J]. 中国基层医药,2008,15(2):267-268.
[7]	成胜权. EB病毒感染的临床多样性与细胞凋亡的遗传基础[J]. 国外医学儿科学分册,1999,26(2):63-65.
[8]	苏犁云,徐锦,孙家娥,等. EB病毒感染实验室诊断方法探讨[J]. 检验医学,2006,21(5):513-516.
[9]	雷宏涛,王杰民,王晓娟,等. EB病毒IgM与DNA检测在小儿EB病毒相关疾病诊断中的价值研究[J]. 陕西医学杂志,2013,42(12):1597-1598.
[10]	沈晓明,王卫平. 儿科学[M]. 7版. 北京:人民卫生出版社,2008:197.

标本类型	例数	EBV DNA阳性 [例（%）]	EBV DNA （对数值）
血浆	328	34（10.37）	3.32±0.93
PBMC	328	98（29.88）^*	3.87±1.07
咽拭子	328	124（37.80）^*#	3.87±1.03

标本类型	例数	EBV DNA阳性 [例（%）]	EBV DNA （对数值）
血浆	328	34（10.37）	3.32±0.93
PBMC	328	98（29.88）^*	3.87±1.07
咽拭子	328	124（37.80）^*#	3.87±1.03

临床表现	EBV DNA阳性[例（%）]	EBV DNA （对数值）
发热、淋巴结肿大	52（41.94）	3.98±1.03
咳嗽、咽喉痛	38（30.65）	3.85±1.02
肝脾肿大	9（7.26）	3.57±1.01
其他	25（20.16）	3.76±1.03

临床表现	EBV DNA阳性[例（%）]	EBV DNA （对数值）
发热、淋巴结肿大	52（41.94）	3.98±1.03
咳嗽、咽喉痛	38（30.65）	3.85±1.02
肝脾肿大	9（7.26）	3.57±1.01
其他	25（20.16）	3.76±1.03

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 10

Related Articles 15

Recommended Articles

Metrics